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Memantine: Can it be Used to Treat Children with
Autism Spectrum Disorder?
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student from Findlay, Ohio; Manoranjan D'Souza M.D., Ph.D., assistant professor of pharmacology
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder characterized by impairment in social, behavior and
communicative skills. The current therapy for ASD only
targets the associated symptoms such as aggression, selfharming acts or temper tantrums but not the core symptoms
of social dysfunction. The pathology of ASD is not fully understood. Interestingly, imaging studies in ASD patients have
reported abnormal high levels of glutamate in certain brain
regions that play an important role in social interaction and
communication. Thus, it has been hypothesized that medications attenuating glutamate transmission may be used as treatment for some of the core symptoms of ASD. Memantine, an
N-methyl-D-aspartate (NMDA) receptor antagonist, has been
approved for the treatment of Alzheimer's disease, and has
shown promise in alleviating some of the symptoms of ASD in
children. In this review, we will discuss the pathology of ASD,
findings from studies that evaluated memantine in ASD patients, the adverse effects of memantine and the potential use
of memantine in the treatment of ASD. Finally, we will discuss
the role of the pharmacist in managing patients with ASD.
Key Terms
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Introduction
Autism spectrum disorder is a heterogeneous neurodevelopmental disordert characterized by core features including
developmental delays in communication and social interaction and repetitive behaviors and/or restricted interests.2
Deficits in communication and social interaction manifest as
shortfalls in "social-emotional reciprocity," nonverbal communication and difficulty with relationships. In addition,
patients with ASD show repetitive behaviors, interests,
movements or atypical interests in sensory aspects of their
environment. The full clinical diagnosis of ASD is defined by
the diagnostic statistical manual-V (DSM-V).
According to the Centers for Disease Control and Prevention
(CDC), in 2012, about one in 68 children were identified with
ASD.3 Interestingly, boys are about five times more likely to be
diagnosed with ASD than girls. Screening for ASD is usually
done at well-child doctor visits.4 If the physician/pedia-trician
notices any abnormalities, such as the ones described above, a
comprehensive diagnostic evaluation is performed, which
includes a detailed evaluation of the child's behavior and development and an interview with the parents. Diagnoses
made by age 2 or older are considered very dependables, but
ASD could possibly be identified before 18 months of age.4
28

Currently, antipsychotic medications rispe1idone and aripiprazole are approved by the U.S. Food and Drug Administration (FDA) for the treatment of associated symptoms of ASD
including aggression, self-harming acts and temper tantrums
commonly seen in autistic patients between 5 and 16 years of
age.6-7 There are currently no FDA approved medications that
directly target the pathological mechanisms underlying autism or treat the core symptoms of ASD described above.
Recent studies, however, suggest abnormalities in glutamate
transmission in autism that could possibly be a target for
treatment. Glutamate is the primary fast-acting excitatory
neurotransmitter within the central nervous system (CNS).s
The actions of glutamate in the CNS are mediated by
ionotropic receptors such as the a-amino-3-hydroxy-5methyl-4-isoxazole propionic acid (AMPA), kainate and
N-methyl-D-aspartate (NMDA) receptors.9 A few clinical
studies have evaluated the effects of memantine, an antagonist of the NMDA glutamate receptor,9 in patients diagnosed
with ASD. In this review, we will first discuss glutamate abnormalities in specific brain regions that have been reported
in ASD patients. In addition, we will discuss findings from
studies that evaluated memantine in ASD patients, the adverse effects of memantine and the potential adverse effects
of memantine in the treatment of ASD. Finally, the role of the
pharmacist in managing ASD patients will be reviewed.
Pathology in Autism Spectrum Disorder
The etiology of ASD is not known, although research has
shown that there is a strong hereditary influence accompanied by genetic mutations.1 More than 20 different mutations
have been identified. Also implicated are further epigenetic
changes, which include modifications in gene expression that
do not change the deoxyribonucleic acid (DNA) sequence.
Overall, the genetic mutations and epigenetic changes affect
proteins that are responsible for neuronal function, cell metabolism, protein synthesis and gene expression.
Irregularities in glutamate concentrations within the brain
have been reported in ASD patients. Concentrations of glutamate in the brain can be measured using proton magnetic
resonance spectroscopy (1H MRS). In a study that utilized tH
MRS, Brown et al. reported elevations in glutamate + glutamine signal (Glx) in certain brain regions of ASD patients.to
For example, the Glx in the auditory cortex was found to be
significantly elevated in the ASD patients when compared to
the control groups. It should be noted that the ASD patients
(n=l3) were ages 25 to 48 years, and they were compared
with healthy adults (n=15) and parents of ASD children not
included in the study (n=15). In addition, Page and colleagues found that adults with ASD (n=20) had a significant
increase in Glx in the amygdala-hippocampal complex
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(P<0.05) compared to healthy patients (n=13J.n Using t H
MRSI (proton magnetic resonance spectroscopic imaging),
Bejjani et al. showed that children with ASD (n=26) had increased Glx in the right pregenual anterior cingulate cortex
(P<0.05) compared to typically developing children (n=16). 1 2
In contrast to the above described studies, some studies report a decrease in Glx signal. For instance, Bernardi et al.
found that the right anterior cingulate cortex had a decreased Glx signal in ASD adults (n=14, P<0.006) than in
healthy controls (n=14).t3 One possible reason for the contrasting findings with respect to anterior cingulate cortex Glx
signal and glutamate levels between the studies of Bernardi
et al. and Bejjani et al. could be due to differences in age of
subjects evaluated in the two studies. For example, subjects
included in the study of Bernardi et al. were adults (age
range 21 to SO years), while the subjects studied in Bejjani et
al. were children (age range 6.1 to 17.S years). In addition,
Horder et al. found that ASD patients had decreased Glx in
the basal ganglia (P<0.0001).14 Overall, the imaging studies
suggest that the direction of alteration in glutamate levels in
ASD patients may be dependent on the age group of patients
and the particular brain region studied.
In addition to irregularities in glutamate levels described
above, alterations in glutamate receptor mRNA expression or
density have been reported in ASD patients. A postmortem
study conducted by Purcell et al. examined brain samples
from the cerebellar cortex of autistic patients (n=lO) and
control patients (n=23), which were matched based upon age
and gender.ts They reported a significant increase (P<0.05)
in levels of AMPA 1, 2, 3 mRNA in the cerebellar samples of
autistic subjects (n=lO) compared to control subjects (n=lO).
Furthermore, increased levels of AMPA 1 (P<0.001) and
NMDA receptor 1 (P<0.05) subunit proteins were reported in
brain samples of autistic subjects (n=9) compared to controls
(n=ll). However, despite elevations in the mRNA and protein levels of specific AMPA and NMDA receptor subunits,
Purcell et al. reported decreased density of AMPA receptors
in the granule (P<0.05) and molecular cell layer (P<0.01) of
the cerebellum in samples of autistic subjects compared to
control subjects using autoradiography. Interestingly, there
was no difference in density of the NMDA receptors in the
different layers of the cerebellum. In summary, the above
evidence from molecular studies suggests elevation of glutamate receptor expression (mRNA and protein) in specific
brain regions in ASD patients.
Binding of glutamate to the NMDA receptor allows the entry
of calcium and sodium ions into the neuron.a This entry of
calcium and sodium ions via opening of the NMDA receptors
results in depolarization and activation of the neurons. However, excessive release of glutamate and activation of the
NMDA receptors can result in excitotoxicity and loss of neurons. Hence, it is hypothesized that attenuating glutamate
transmission will have a neuroprotective effect and prevent
loss of existing neurons. Consequently, memantine, a noncompetitive NMDA receptor antagonist,9 may provide the
desired neuroprotective effects and promotion of neurogene·
sis. Currently, memantine is approved by the FDA for
Fall 2014 Volume 6, Issue 1
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moderate to severe dementia caused by Alzheimer's disease.
Several studies have evaluated memantine in children with
ASD. Because the DSM-V criteria for ASD were released only
recently (May 2013), most of the studies described in this
article have used the DSM-IV-TR criteria, which was the
standard criteria at the time the studies were conducted.
Clinical evaluation of Memantine in ASD
In a retrospective observational study, Erickson et al. evalu·
ated the effects of memantine on symptoms associated with
autism, such as social withdrawal, communication impairment, irritability and inattention/hyperactivity.1 6 The study
included 18 patients (mean age of 11.4 years) who had more
than one symptom and were treated at an outpatient treatment center for autism. All patients were evaluated by psychiatrists and met the DSM-IV-TR criteria for autism. Patients
began with either 2.Smg or Smg memantine daily depending
on their weight, which was titrated up by either 2.Smg or Smg
every two weeks to a maximum of 20mg daily or until a response or side effects were observed. Thirteen patients were
taking concurrent medications, mainly anticonvulsants, antidepressants or second-generation antipsychotics, which were
maintained during the trial. Of those taking secondgeneration antipsychotics, three patients were either on
risperidone or aripiprazole, which are FDA approved medications for autism patients. A clinical global impressionsseverity subscale (CGl-S) and CG I-Improvement subscale (CGI
-I) was completed at baseline and during clinic visits to document changes in symptoms. The CGI-S was rated from
1 to 7 (1-normal, 7-extremely ill) while the CGl-1 was also rated from 1 to 7 (1-very much improved, 7-very much worse).
Patients with a CGI-1 rating of 1 or 2 after the trial were considered treatment responders. Only six patients had completed scores at baseline and post-trial conducted on the aberrant
behavior checklist-community (ABC-C) irritability subscale, a
58-item subscale used to assess disruptive behavior and developmental disabilities. The range of the study period was
1.5 to 56 weeks (mean of 19.3 weeks) with a mean dose of
10.lmg/day. The CGI-S scores showed a significant decrease
from baseline (p<0.01) although the CGl-1 improvement was
not substantial. Patients with CGl-I ratings of much improved
(n=6) or very much improved (n=S) were considered as treatment responders. For patients who did have ABC data, the
only significant improvement was the hyperactivity subscale
(p<0.05). Adverse effects occurred in seven of the patients
and included irritability (n=4), rash (n=l), emesis (n=l), increased seizure frequency (n=l) and excessive sedation
(n=l). Two patients stopped treatment due to unresponsiveness, while four stopped treatment because of adverse effects.
Overall, the results reflected the beneficial use of memantine,
especially in improving social interaction and attention. There
were, however, several limitations to this study. The sample
size of the study was small, thus making it difficult to form
true associations within this observational study. The length
of the treatment for each patient was not addressed by the
authors, which varied and may not have allowed enough time
to determine the efficacy and side effects of memantine.
Importantly, only five patients were on monotherapy with
memantine during the study, indicating that the other 13 patients were taking other concurrent medications, which could

THE PHARMACY AND WELLNESS REVIEW

29

CNS

Memantine: Can it be Used to Treat Children with Autism Spectrum Disorder?

have influenced the data with their varying therapies. Lastly,
ratings on the CGI scales were not made by the same physician
for each patient, indicating that scores may have been affected
by the subjective impressions of the different physicians.
An open-label study by Chez et al. evaluated the efficacy of
memantine in the treatment of language and social behavioral symptoms in patients diagnosed with autism.17 The study
included 151 patients who were found eligible through dinical observation and the DSM-IV criteria for autism (n=105)
and pervasive developmental disorder not otherwise specified (POD-NOS; n=46). Pervasive developmental disorder is
characterized by severe impairment in developing reciprocal
social interaction due to impaired communication skills or
behavior.is Patients were predominantly male (mean age of
9.31 years). Those taking concurrent medications, which
were primarily selective serotonin reuptake inhibitors, atypical antipsychotics, stimulants, alpha-adrenergic antagonists
and cholinesterase inhibitors, were required to take them
consistently for at least eight weeks before treatment and
during the study. Of these patients, 31 were taking risperidone, while five were taking aripiprazole. Patients with Fragile X or Rett syndrome genetic disorders, metabolic disorders
or brain malformations were excluded from the study. The
starting dose ofmemantine was 5mg/day, which was titrated
up or down every four to six weeks in 2.5 or 5mg increments
up to 30mg/day. Patient follow-up was carried out via
phone calls or email every four weeks and clinical assessments were conducted every eight to 12 weeks. The duration of the study had a range of one to 20 months
(mean=9.27 months). Assessments of the treatment were
conducted by a primary clinician and caretaker through interviews, diaries, clinical examinations and observations.
These were translated onto the CGl-1 seven-point scale for
language by examining receptive skills and utterances, behavior through cognitive improvement in social interactions
and self-stimulatory activity by observing the amount and
type of patient activity. The CGI-1 for behavior was observed
through social interaction, ability to cooperate at home and
school and attentiveness to others. A score of either 1 or 2
was considered to be significant improvement in all three
categories. The CGI-I for language and behavior had a significant improvement in about 70 percent of both autism and
POD-NOS patients together, with changes occurring in the
first two to four weeks. Improvement was also found to increase as length of therapy increased. When excluding the
POD-NOS patients, however, language improvement in autism alone was not found to be significant More specifically,
65/105 and 67 /105 autism patients were found to have ratings of significant improvement in language and behavior
respectively. When excluding those who stopped treatment,
language improvement was still significant for both the autistic
and POD-NOS patient groups, while behavioral improvement
was not Lastly, for the CGl-1 for self-stimulatory stereotypic
behaviors, only those observed with these behaviors at baseline were included (n=l16). Only nine of the patients with
autism were found to have significant improvement and
there was found to be no progress in self-stimulatory behavior and duration of treatment overall for both autism and
POD-NOS patients. From the sample, 22 patients experienced
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worsening of symptoms and dropped out, while five patients
stopped therapy because of a lack of response. Although abnormal electroencephalography findings were observed in
patients, these changes were concluded to be normal for this
patient population. For patients with concurrent therapy,
hematological, serum chemistry and hepatic profiles were
examined and found to have no changes. The results of the
study seem to suggest that memantine is a safe adjunct therapy for patients with autism for improvement of language and
behavioral symptoms. Importantly the study showed that
memantine resulted in improvement of language and behavioral symptoms in a majority of patients, although improvements were not statistically significant when patients who
withdrew from the study were excluded from the analysis. A
major limitation of the study was that the researchers relied
on CGI-1 subscale scores, which were not scored by the same
clinician or caretakers, indicating possible subjectivity in ratings, which may have affected the results. Furthermore, concurrent medications being taken by the patients were not the
same for all the patients and may have influenced the results.
Ghaleiha et al. examined the effects of memantine as an adjunct therapy with risperidone.19.zo Forty children between
the ages of 4 and 12 years (mean age of 7.42 years), who met
the diagnostic DSM IV-TR criteria for autism confirmed by a
child psychologist, were included in the 10-week doubleblind randomized placebo-controlled trial. Inclusion criteria
also comprised a screening and baseline ABC-C irritability
subscale score of<:: 12. Children who had concomitant schizophrenia, psychotic disorders, a history of drug or alcohol
abuse, tardive dyskinesia, active clinical seizures, significant
medical problems, had taken memantine previously or had
taken an antipsychotic drug treatment six months before
enrollment began were excluded from the study. Patients
were randomized into two equal parallel groups, and an
equal number of girls and boys were included in each group.
One group received memantine and risperidone, while the
other group received a placebo and risperidone. The starting
dose of risperidone was 0.5mg tablet/day, which was gradually titrated up 0.5mg weekly to a maximum of 2mg/day for
children weighing 10 to 40kg, and a maximum of 3mg/day
for children weighing >40kg. Memantine doses started at
5mg caplet/day and were titrated up or down in 5mg increments each week to a maximum of 15mg/day for children
weighing 10 to 40kg and 20mg/day for children weighing
>40kg. All drugs, including placebo, began at the same time
and any psychosocial intervention therapy was stopped. The
primary outcome was the irritability subscale measured by
the ABC-C. This was used to evaluate five types of behavioral
abnormalities, where three were core deficits (lethargy/
social withdrawal, stereotypic behavior, inappropriate
speech) and two were associated disturbances (irritability,
hyperactivity/noncompliance). Ratings on the ABC-C scale
followed standardized instructions by a trained resident of
psychiatry and the children's parents every two weeks.
Scores at baseline were compared to scores during treatment
weeks 2, 4, 6, 8, and 10 (end point). The extrapyramidal
symptoms rating scale was also used to measure extrapyramidal symptoms, such as tardive dyskinesia, akinesia, akathisia and parkinsonism.21 Independent raters and a medical

THE PHARMACY AND WELLNESS REVIEW

Fall 2014 Volume 6, Issue 1

Memantine: Can it be Used to Treat Children with Autism Spectrum Disorder?

student documented side effects every two weeks. All patients were able to complete the trial and none were lost to
follow-up. The memantine treatment group showed a significant difference in ratings when compared to the placebo in
the ABC-C irritability, stereotypic behavior and hyperactivity/noncompliance subscales. No significant difference was
observed in the lethargy/social withdrawal or inappropriate
speech subscales. In addition, there were no significant differences found between groups in extrapyramidal symptoms
or the frequency of side effects, which included abdominal
pain, changes in appetite, dizziness, insomnia, nausea, sedation and rash. There were several limitations of the study.
Primarily, the short trial duration of 10 weeks did not allow
for an extended length of time to observe side effects, and/or
efficacy of memantine in causing symptomatic improvement
Furthermore, different scorers for the different subscales
could have led to subjective variability in ratings, which
could have influenced the data. Overall, the results of the trial
indicated a positive effect of memantine on one core and two
associated symptoms of autism.
More recently, five clinical trials of memantine use in pediatric patients with ASD were completed and Forest Pharmaceuticals submitted the results for review by the FDA in June
2014.22 The complete trial details of these studies were unavailable at the time of writing this article. However, the FDA
clinical review is available on its website and has provided
some insight into the trials. Two of the five studies were reviewed for the efficacy of memantine in pediatric (ages 6 to
12 years) ASD patients. Both studies were 12-week doubleblind placebo controlled trials with 114 patients in MD-57A
and 471 patients in MD-68. The MD-S7A trial was a two-part
trial. The first part of the trial was excluded from the clinical
review because it was open-labeled. The second part of the
trial consisted of patients who met DSM-IV specifications for
autism according to the autism diagnostic observation schedule (ADOS) and the autism diagnostic interview-revised
(ADI-R). These patients were then placed on two weeks of
single-blind placebo. By the end of the two weeks, if the patients still met the inclusion criteria, they were randomized
to either placebo or weight-based flexible-fixed memantine
doses (3 to 15mg) in a 1:1 ratio. The primary efficacy endpoint of the 12-week trial was the mean change from baseline of the SRS (social responsiveness scale) scores at the end
of the trial. According to the FDA clinical review, memantine
did not show superiority to placebo treatment. The common
adverse events observed in this trial were agitation, ear infection, affective disorder, allergic rhinitis, influenza, laceration, enuresis and frequent bowel movements.
Table 1. Memantine's dosage forms and prices.*2s
Namenda: Tablets, oral
Namenda Titration Pak: Tablets, oral

CNS

The MD-68 trial was a parallel group, multicenter, doubleblind, randomized, withdrawal study with 471 ASD patients
between the ages of 6 and 12 years. In addition, these patients had already completed 12 weeks of open-label memantine administration and had at least a 10 point decrease
in the SRS total raw score in the MD-91 trial. Patients were
then randomized in a 1:1:1 ratio with full dose memantine, 50
percent memantine dose or placebo. According to the FDA
clinical review, memantine did not demonstrate superiority to
placebo. Also, the adverse events observed in the trial were of
little clinical significance in the opinion of the clinical reviewer. Dose related adverse events were not observed, but the
lead-in study may have affected these results. Based on these
more recent studies, the FDA clinical review recommended
approval of the memantine indication for adolescents/
children with autism despite lack of efficacy to treat the core
symptoms of autism. Further scrutiny of the data and the FDA
clinical review will only be possible when the complete studies are available for review to the larger clinical community.
In summary, studies published to date in the literature assessing memantine either as an adjunct therapy or monotherapy for the core symptoms of ASD had limitations either
due to small sample size or study design. Therefore, these
trials have limited external validity. Although all of these
published studies suggested positive benefit using memantine, further double-blind studies with robust sample sizes
and study design will be required to determine the role of
memantine in the treatment of ASD patients. Based on more
recent studies, the data of which is available only to the FDA
currently, the FDA clinical review has recommended approval of memantine for treatment of ASD in adolescents/
children despite lack of clinical efficacy.22 However, Forest
Pharmaceuticals, memantine's manufacturer, does not plan
to seek a pediatric indication of memantine at this time.
Pharmacist Role and Counseling Points
Memantine is approved by the FDA to treat moderate-tosevere Alzheimer's disease. Memantine is prescribed
off-label for treatment of ASD as described above, and the
pharmacist has a significant role in educating parents and
patients about the therapeutic efficacy and adverse effects of
memantine for this patient population.23
Memantine is available in several dosage forms including
tablets, capsules in extended release forms and a solution.
The cost varies depending on the dosage forms and strengths
(See Table 1). Namenda® titration packs are blister packages
containing 49 tablets of 28 x Smg and 21x10mg. Namenda®

Namenda XR Titration Pack Oral : Capsules, extended release, oral

5mg (60), IOmg (60)
5mg (28), JO mg (21)
7mg (30)
14mg(90)
2 lmg(30)
28mg(90)
7mg (7), l 4mg (7), 21 mg (7), 28mg (7)

$374.99
$306.18
$356.26
$1068.74
$356.26
$1068.74
$332.5 1

Namenda : Solution, oral

2mg/mL (360mL)

$725.32

Namenda XR : Capsules, extended release, oral

* Costs without insurance coverage
Fall 2014 Volume 6, Issue 1
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extended release titration packs are blister packages containing 28 capsules of 7 x 7mg, 7 x 14mg, 7 x 2 lmg and 7 x 28mg.
The solution form may contain sorbitol, and capsules may
contain sugar.24 0ral pediatric dosing adjustment is not yet
established, but the clinical studies involving adolescents
start with a low dose of 2.Smg daily or Smg daily, and titrate
up to maximum of 15mg, 20mg or 30mg daily depending on
the weight of the patientt6,11,19
Memantine is well tolerated with low adverse events when it
is used to treat dementia. In addition, no significant side effects were observed when the medication was given to
adolescents for autism. Adverse reactions are similar to immediate and extended release formulations. If the patient has
hypersensitivity to memantine or any component of the .formulation, the drug should not be used. Bupropion, carbonic
anhydrase inhibitors, sodium bicarbonate and trimethoprim
are known to interact with memantine. Memantine is a substrate of organic cation transporter (OCT 2), and bupropion
may increase the serum concentration of OCT 2 substrates.
Carbonic anhydrase inhibitors and sodium bicarbonate may
decrease the excretion of memantine with the exception of
brinzolamide and dorzolamide. Trimethoprim may enhance
the adverse and toxic effects, especially the risk of myoclonus
and/or delirium. Therefore, these four drugs should be monitored when memantine is given to patients. 2s
The CDC has analyzed several alternative treatment options
including behavior and communication approaches, dietary

approaches and complementary and alternative medicine
(CAM). One behavior and communication approach, known
as applied behavior analysis (ABA), is a widely accepted
treatment option to help children with ASD. The objective of
ABA treatment is to encourage positive behaviors and discourage negative behaviors so that patients can progress
toward positive activities. Applied behavior analysis includes
different types of treatment, and other therapies can be a
part of a program (See Table 2). Dietary approaches are not
recommended because treatments are based on the unproven idea that some food or lack of vitamins and minerals may
cause symptoms of autism. Removing certain types of foods
may be harmful to a child, so refer to the physician if this
treatment option is being considered. In addition, CAM is not
recommended. Complementary and alternative medicine
includes special diets, chelation (a treatment to remove
heavy metals such as lead from the body) and body-based
systems such as deep pressure. The efficacy of these treatments are very controversial and may even cause dangerous
consequences to a child's health. Therefore, patients should
consult with their physician prior to implementing treatment;.26

Conclusion
Currently, there are no medications to treat the core symptoms of autism such as communication and social deficits.
The FDA approved medications for autism, namely risperidone and aripiprazole, treat related symptoms of aggression,
self-harming acts or temper tantrums in children between

Table 2. Description of Applied Behavior Analysis (ABA) and Other Therapies.26
ABA

Discrete Trial Training (DTT)

Broken down into smaller steps.
Rewards for positive behaviors and
incorrect answers are ignored.

Early Intensive Behavior Intervention
(EIBI)

ABA for younger children of usually
younger than 5 or often younger than 3.

Pivotal Response Training (PRT)

Focus on communication and social
skills.

Verbal Behavior Intervention (VBI)

Focus on verbal ski lls.

Developmental, Individual Differences, Relationship-Based Approach
(DIR; "Floor time")

Focus on emotional and relational
development. Focus on how the child
reacts to sights, sounds and smells.

Treatment and Education of Autistic and related Communication-handicapped
Children (TEACCH)

Use visual aids such as picture cards.
Focus on the child's daily activities such
as dressing, eating, bathing, and relating
to people. Reinforce independence.
Focus on sensory information to help a
child who is disturbed by sounds or
touch.

Occupational Therapy

Sensory Integration Therapy
Speech Therapy

Focus on communication skills.

The Picture Exchange Communication System (PECS)

Use picture symbols to improve
communication skills.

32
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the ages of 5 and 16 years. An FDA approved drug for treating Alzheimer's disease, memantine, has been suggested as a
possible treatment option to treat the core symptoms of ASD.
Imaging studies report increased glutamate levels in certain
brain regions in ASD patients. Similarly, postmortem studies
suggest increased mRNA levels of NMDA receptors in certain
brain regions of ASD patients. Consistent with these findings,
several published clinical studies reviewed here demonstrate
possible benefits of using memantine, an NMDA antagonist.
However, the studies published thus far are not very robust
due to their small sample sizes and weak study designs.
Based on studies still not available to the larger scientific
community, the FDA clinical review has recently recommended approval of memantine for use in ASD patients
despite lack of efficacy. Pharmacists must undertake a significant role in understanding memantine's use in ASD patients
in light of unreliable efficacy, as well as in understanding other therapies widely utilized for ASD management
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